Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia

Molecular Psychiatry

Volumn 23, Issue 2, 2018, Pages 323-334

  Notter, T ^a   Coughlin, J M ^b   Gschwind, T ^a   Weber Stadlbauer, U ^a   Wang, Y ^b   Kassiou, M ^c,d   Vernon, A C ^e   Benke, D ^a   Pomper, M G ^b   Sawa, A ^b   Meyer, U ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; CYTOKINE; KAINIC ACID; TRANSLOCATOR PROTEIN 18 KDA; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; BIOLOGICAL MARKER; BZRP PROTEIN, MOUSE; TSPO PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR DISORDER; CELLS BY BODY ANATOMY; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GLIOSIS; LIGAND BINDING; MALE; MICROGLIA; MIDDLE FRONTAL GYRUS; MOUSE; NERVOUS SYSTEM INFLAMMATION; NERVOUS TISSUE; NONHUMAN; ONSET AGE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR ENDOTHELIAL CELL; ADULT; ANIMAL; BLOOD; C57BL MOUSE; DIAGNOSTIC IMAGING; DISEASE MODEL; HUMAN; IMMUNOMODULATION; INFLAMMATION; METABOLISM; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES;

ADULT; ANIMALS; ASTROCYTES; BIOMARKERS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEUROIMMUNOMODULATION; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, GABA; SCHIZOPHRENIA;

EID: 85009826731     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.248     Document Type: Article

References (105)

1. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016; 388: 86-97.
2. Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull 2013; 39: 1174-1179.
3. Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2015; 2: 258-270.
4. Landek-Salgado MA, Faust TE, Sawa A. Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry 2016; 21: 10-28.
5. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167: 261-280.
6. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 20-34.
7. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63: 801-808.
8. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016; 21: 1696-1709.
9. Hayes LN, Severance EG, Leek JT, Gressitt KL, Rohleder C, Coughlin JM et al. Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr Bull 2014; 40: 963-972.
10. Volk DW, Chitrapu A, Edelson JR, Roman KM, Moroco AE, Lewis DA. Molecular mechanisms and timing of cortical immune activation in schizophrenia. Am J Psychiatry 2015; 172: 1112-1121.
11. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 2013; 18: 206-214.
12. Trépanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry 2016; 21: 1009-1026.
13. Bernstein HG, Steiner J, Guest PC, Dobrowolny H, Bogerts B. Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophr Res 2015; 161: 4-18.
14. Fillman SG, Sinclair D, Fung SJ, Webster MJ, Shannon Weickert C. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl Psychiatry 2014; 4: e365.
15. Fillman SG, Weickert TW, Lenroot RK, Catts SV, Bruggemann JM, Catts VS et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume. Mol Psychiatry 2016; 21: 1090-1098.
16. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-671.
17. Mondelli V, Ciufolini S, Belvederi Murri M, Bonaccorso S, Di Forti M, Giordano A et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr Bull 2015; 41: 1162-1170.
18. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029-1034.
19. Meyer U, Schwarz MJ, Müller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 2011; 132: 96-110.
20. Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol 2013; 27: 337-342.
21. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014; 40: 181-191.
22. Pasternak O, Kubicki M, Shenton ME. In vivo imaging of neuroinflammation in schizophrenia. Schizophr Res 2016; 173: 200-212.
23. Watkins CC, Andrews SR. Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophr Res 2016; 176: 14-22.
24. Owen DR, Matthews PM. Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. Int Rev Neurobiol 2011; 101: 19-39.
25. Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-Fregonara P, Bertoldo A et al. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans 2015; 43: 586-592.
26. Vivash L, O'Brien TJ. Imaging microglial activation with TSPO PET: lighting up neurologic diseases? J Nucl Med 2016; 57: 165-168.
27. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol 2006; 80: 308-322.
28. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère JJ, Lindemann P et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-409.
29. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010; 9: 971-988.
30. Gut P, Zweckstetter M, Banati RB. Lost in translocation: the functions of the 18-kD translocator protein. Trends Endocrinol Metab 2015; 26: 349-356.
31. Sandiego CM, Gallezot JD, Pittman B, Nabulsi N, Lim K, Lin SF et al. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc Natl Acad Sci USA 2015; 112: 12468-12473.
32. 11 C]PBR28 positron emission tomography in nonhuman primates. Neuroimage 2012; 63: 232-239.
33. Papadopoulos V, Lecanu L. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp Neurol 2009; 219: 53-57.
34. Kreisl WC, Lyoo CH, Liow JS, Wei M, Snow J, Page E et al. (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease. Neurobiol Aging 2016; 44: 53-61.
35. Janssen B, Vugts DJ, Funke U, Molenaar GT, Kruijer PS, van Berckel BN et al. Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. Biochim Biophys Acta 2016; 1862: 425-441.
36. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C] PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-822.
37. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009; 50: 1801-1807.
38. Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR et al. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: An [(11)C]PBR28 PET brain imaging study. Am J Psychiatry 2016; 173: 44-52.
39. Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G et al. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18 F]-FEPPA. Schizophr Bull 2015; 41: 85-93.
40. Takano A, Arakawa R, Ito H, Tateno A, Takahashi H, Matsumoto R et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol 2010; 13: 943-950.
41. Coughlin JM, Wang Y, Ambinder EB, Ward RE, Minn I, Vranesic M et al. In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry 2016; 6: e777.
42. Hafizi S, Tseng HH, Rao N, Selvanathan T, Kenk M, Bazinet RP et al. Imaging microglial activation in untreated first-episode psychosis: A PET study with [18F] FEPPA. Am J Psychiatry; e-pub ahead of print 9 September 2016; doi: appiajp201616020171.
43. Holmes SE, Hinz R, Drake RJ, Gregory CJ, Conen S, Matthews JC et al. In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study. Mol Psychiatry 2016; 21: 1672-1679.
44. Chauveau F, Boutin H, Van Camp N, Dollé F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging 2008; 35: 2304-2319.
45. Endres CJ, Pomper MG, James M, Uzuner O, Hammoud DA, Watkins CC et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 2009; 50: 1276-1282.
46. Meyer U, Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 2010; 90: 285-326.
47. Meyer U. Prenatal poly(I:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry 2014; 75: 307-315.
48. Meyer U, Feldon J, Fatemi SH. In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci Biobehav Rev 2009; 33: 1061-1079.
49. Reisinger S, Khan D, Kong E, Berger A, Pollak A, Pollak DD. The poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery. Pharmacol Ther 2015; 149: 213-226.
50. Meyer U, Feldon J, Schedlowski M, Yee BK. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 2005; 29: 913-947.
51. Garay PA, Hsiao EY, Patterson PH, McAllister AK. Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development. Brain Behav Immun 2013; 31: 54-68.
52. Giovanoli S, Weber-Stadlbauer U, Schedlowski M, Meyer U, Engler H. Prenatal immune activation causes hippocampal synaptic deficits in the absence of overt microglia anomalies. Brain Behav Immun 2016; 55: 25-38.
53. Lévesque M, Avoli M. The kainic acid model of temporal lobe epilepsy. Neurosci Biobehav Rev 2013; 37: 2887-2899.
54. Zattoni M, Mura ML, Deprez F, Schwendener RA, Engelhardt B, Frei K et al. Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. J Neurosci 2011; 31: 4037-4050.
55. Vezzani A, Conti M, De Luigi A, Ravizza T, Moneta D, Marchesi F et al. Interleukin- 1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 1999; 19: 5054-5065.
56. De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M, Marchesi F et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci 2000; 12: 2623-2633.
57. Pernot F, Heinrich C, Barbier L, Peinnequin A, Carpentier P, Dhote F et al. Inflammatory changes during epileptogenesis and spontaneous seizures in a mouse model of mesiotemporal lobe epilepsy. Epilepsia 2011; 52: 2315-2325.
58. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001; 156: 234-258.
59. Dodell-Feder D, Tully LM, Hooker CI. Social impairment in schizophrenia: new approaches for treating a persistent problem. Curr Opin Psychiatry 2015; 28: 236-242.
60. Crawley JN. Translational animal models of autism and neurodevelopmental disorders. Dialogues Clin Neurosci 2012; 14: 293-305.
61. Vuillermot S, Weber L, Feldon J, Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010; 30: 1270-1287.
62. Weber-Stadlbauer U, Richetto J, Labouesse MA, Bohacek J, Mansuy IM, Meyer U. Transgenerational transmission and modification of pathological traits induced by prenatal immune activation. Mol Psychiatryt; e-pub ahead of print 29 March 2016; doi: 10.1038/mp.2016.41.
63. Notter T, Panzanelli P, Pfister S, Mircsof D, Fritschy JM. A protocol for concurrent high-quality immunohistochemical and biochemical analyses in adult mouse central nervous system. Eur J Neurosci 2014; 39: 165-175.
64. Selemon LD, Zecevic N. Schizophrenia: a tale of two critical periods for prefrontal cortical development. Transl Psychiatry 2015; 5: e623.
65. Tamminga CA, Stan AD, Wagner AD. The hippocampal formation in schizophrenia. Am J Psychiatry 2010; 167: 1178-1193.
66. Ralvenius WT, Benke D, Acuña MA, Rudolph U, Zeilhofer HU. Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype. Nat Commun 2015; 6: 6803.
67. Burguillos MA. Use of meso-scale discovery™ to examine cytokine content in microglia cell supernatant. Methods Mol Biol 2013; 1041: 93-100.
68. Kim T, Pae AN. Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1). Expert Opin Ther Pat 2016; 13: 1-27.
69. Owen DR, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC et al. Mixedaffinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med 2011; 52: 24-32.
70. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2012; 32: 1-5.
71. Petrides M, Pandya DN. Dorsolateral prefrontal cortex: comparative cytoarchitectonic analysis in the human and the macaque brain and corticocortical connection patterns. Eur J Neurosci 1999; 11: 1011-1036.
72. Kikinis Z, Fallon JH, Niznikiewicz M, Nestor P, Davidson C, Bobrow L et al. Gray matter volume reduction in rostral middle frontal gyrus in patients with chronic schizophrenia. Schizophr Res 2010; 123: 153-159.
73. Uylings HB, Groenewegen HJ, Kolb B. Do rats have a prefrontal cortex? Behav Brain Res 2003; 146: 3-17.
74. Seamans JK, Lapish CC, Durstewitz D. Comparing the prefrontal cortex of rats and primates: insights from electrophysiology. Neurotox Res 2008; 14: 249-262.
75. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539.
76. Malkova NV, Yu CZ, Hsiao EY, Moore MJ, Patterson PH. Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav Immun 2012; 26: 607-616.
77. Schwartzer JJ, Careaga M, Onore CE, Rushakoff JA, Berman RF, Ashwood P. Maternal immune activation and strain specific interactions in the development of autism-like behaviors in mice. Transl Psychiatry 2013; 3: e240.
78. Kreisl WC, Jenko KJ, Hines CS, Lyoo CH, Corona W, Morse CL et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab 2013; 33: 53-58.
79. Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 2009; 35: 306-328.
80. Ji B, Maeda J, Sawada M, Ono M, Okauchi T, Inaji M et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci 2008; 28: 12255-12267.
81. Bae KR, Shim HJ, Balu D, Kim SR, Yu SW. Translocator protein 18 kDa negatively regulates inflammation in microglia. J Neuroimmune Pharmacol 2014; 9: 424-437.
82. Ma L, Zhang H, Liu N, Wang PQ, Guo WZ, Fu Q et al. TSPO ligand PK11195 alleviates neuroinflammation and beta-amyloid generation induced by systemic LPS administration. Brain Res Bull 2016; 121: 192-200.
83. Zhang H, Ma L, Yin YL, Dong LQ, Cheng GG, Ma YQ et al. Over-expression of TSPO in the hippocampal CA1 area alleviates cognitive dysfunction caused by lipopolysaccharide in mice. Brain Res 2016; 1646: 402-409.
84. Daugherty DJ, Selvaraj V, Chechneva OV, Liu XB, Pleasure DE, Deng W. A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol Med 2013; 5: 891-903.
85. Ravikumar B, Crawford D, Dellovade T, Savinainen A, Graham D, Liere P et al. Differential efficacy of the TSPO ligands etifoxine and XBD-173 in two rodent models of multiple sclerosis. Neuropharmacology 2016; 108: 229-237.
86. Gut P. Targeting mitochondrial energy metabolism with TSPO ligands. Biochem Soc Trans 2015; 43: 537-542.
87. Morin D, Musman J, Pons S, Berdeaux A, Ghaleh B. Mitochondrial translocator protein (TSPO): From physiology to cardioprotection. Biochem Pharmacol 2016; 105: 1-13.
88. Batoko H, Veljanovski V, Jurkiewicz P. Enigmatic translocator protein (TSPO) and cellular stress regulation. Trends Biochem Sci 2015; 40: 497-503.
89. Banati RB, Middleton RJ, Chan R, Hatty CR, Kam WW, Quin C et al. Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat Commun 2014; 5: 5452.
90. Coughlin JM, Ishizuka K, Kano SI, Edwards JA, Seifuddin FT, Shimano MA et al. Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia. Mol Psychiatry 2013; 18: 10-11.
91. Steullet P, Cabungcal JH, Monin A, Dwir D, O'Donnell P, Cuenod M et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology? Schizophr Res 2016; 176: 41-51.
92. Kulak A, Steullet P, Cabungcal JH, Werge T, Ingason A, Cuenod M et al. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxid Redox Signal 2013; 18: 1428-1443.
93. Cabungcal JH, Counotte DS, Lewis EM, Tejeda HA, Piantadosi P, Pollock C et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron 2014; 83: 1073-1084.
94. Oskvig DB, Elkahloun AG, Johnson KR, Phillips TM, Herkenham M. Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response. Brain Behav Immun 2012; 26: 623-634.
95. Bubser M, Koch M. Prepulse inhibition of the acoustic startle response of rats is reduced by 6-hydroxydopamine lesions of the medial prefrontal cortex. Psychopharmacology 1994; 113: 487-492.
96. Japha K, Koch M. Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: reversal by haloperidol. Psychopharmacology 1999; 144: 347-354.
97. Yee BK. Cytotoxic lesion of the medial prefrontal cortex abolishes the partial reinforcement extinction effect, attenuates prepulse inhibition of the acoustic startle reflex and induces transient hyperlocomotion, while sparing spontaneous object recognition memory in the rat. Neuroscience 2000; 95: 675-689.
98. Schwabe K, Koch M. Role of the medial prefrontal cortex in N-methyl-D-aspartate receptor antagonist induced sensorimotor gating deficit in rats. Neurosci Lett 2004; 355: 5-8.
99. Oh U, Fujita M, Ikonomidou VN, Evangelou IE, Matsuura E, Harberts E et al. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol 2011; 6: 354-361.
100. Colasanti A, Guo Q, Muhlert N, Giannetti P, Onega M, Newbould RD et al. In vivo assessment of brain white matter inflammation in multiple sclerosis with 18 FPBR111 PET. J Nucl Med 2014; 55: 1112-1118.
101. Narendran R, Frankle WG. Comment on analyses and conclusions of "Microglial Activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C] PBR28 PET brain imaging study". Am J Psychiatry 2016; 173: 536-537.
102. Boutin H, Chauveau F, Thominiaux C, Grégoire MC, James ML, Trebossen R et al. 11C DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. J Nucl Med 2007; 48: 573-581.
103. Chauveau F, Van Camp N, Dollse F, Kuhnast B, Hinnen F, Damont A et al. Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18 F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med 2009; 50: 468-476.
104. Xie L, Yamasaki T, Ichimaru N, Yui J, Kawamura K, Kumata K et al. [11C]DAC-PET for noninvasively monitoring neuroinflammation and immunosuppressive therapy efficacy in rat experimental autoimmune encephalomyelitis model. J Neuroimmune Pharmacol 2012; 7: 231-242.
105. Miyashita T. Confocal microscopy for intracellular co-localization of proteins. Methods Mol Biol 2015; 1278: 515-526.